Using cancer cell lines (the original TPC1 cell line and its derivatives), they found higher numbers of CD44+/CD24− cells in the more aggressive cell lines (positivity rates being 86% in highly tumorigenic TPC-1Mice cells, >73% in moderately tumorigenic TPC-1SC2 cells, >21% in parental, poorly tumorigenic TPC-1 cells). This evidence concerns the gene CD44 and cancer.